FLT3 and myelodysplastic syndrome: A phase I/II trial for patients with AML and MDS showed that the combination of midostaurin and a DMNT inhibitor 5‐azacytidine was an effective and safe regime, especially for patients with FLT3 mutations but not previously exposed to other FLT3 inhibitors.254